#somatostatin

[mitalipingale]

https://homment.com/LjfQjrh5JcxKydtvQL3g

The Somatostatin Analogs Market in 2023 is US$ 7 billion, and is expected to reach US$ 13.17 billion by 2031 at a CAGR of 8.20%.

[mindblowingscience]

Researchers have identified a component within the venom of a predatory marine cone snail, the geography cone, that mimics a human hormone called somatostatin, which regulates the levels of blood sugar and various hormones in the body. The hormone-like toxin’s specific, long-lasting effects, which help the snail hunt its prey, could also help scientists design better drugs for people with diabetes or hormone disorders, conditions that can be serious and sometimes fatal. The results appear in the journal Nature Communications.

Continue Reading.

[compneuropapers]

Interesting Papers for Week 21, 2024

Suboptimal multisensory processing in pediatric migraine without aura: a comparative, cross-sectional study. Braunitzer, G., Tót, K., Eördegh, G., Hegedűs, A., Kiss, Á., Kóbor, J., … Nagy, A. (2023). Scientific Reports, 13, 19422.

Active cortical networks promote shunting fast synaptic inhibition in vivo. Burman, R. J., Brodersen, P. J. N., Raimondo, J. V., Sen, A., & Akerman, C. J. (2023). Neuron, 111(22), 3531-3540.e6.

Alpha-frequency feedback to early visual cortex orchestrates coherent naturalistic vision. Chen, L., Cichy, R. M., & Kaiser, D. (2023). Science Advances, 9(45).

Functional alterations of the prefrontal circuit underlying cognitive aging in mice. Chong, H. R., Ranjbar-Slamloo, Y., Ho, M. Z. H., Ouyang, X., & Kamigaki, T. (2023). Nature Communications, 14, 7254.

Early Action Error Processing Is Due to Domain-General Surprise, Whereas Later Processing Is Error Specific. Choo, Y., Mather, A., & Wessel, J. R. (2023). Journal of Neuroscience, 43(45), 7678–7689.

The roles of surround inhibition for the intrinsic function of the striatum, analyzed in silico. Frost Nylén, J., Hjorth, J. J. J., Kozlov, A., Carannante, I., Hellgren Kotaleski, J., & Grillner, S. (2023). Proceedings of the National Academy of Sciences, 120(45), e2313058120.

Selective plasticity of fast and slow excitatory synapses on somatostatin interneurons in adult visual cortex. Grier, B. D., Parkins, S., Omar, J., & Lee, H.-K. (2023). Nature Communications, 14, 7165.

Dopaminergic systems create reward seeking despite adverse consequences. Jovanoski, K. D., Duquenoy, L., Mitchell, J., Kapoor, I., Treiber, C. D., Croset, V., … Waddell, S. (2023). Nature, 623(7986), 356–365.

Association neurons in the crow telencephalon link visual signs to numerical values. Kirschhock, M. E., & Nieder, A. (2023). Proceedings of the National Academy of Sciences, 120(45), e2313923120.

A mechanistic insight into sources of error of visual working memory in multiple sclerosis. Motahharynia, A., Pourmohammadi, A., Adibi, A., Shaygannejad, V., Ashtari, F., Adibi, I., & Sanayei, M. (2023). eLife, 12, e87442.3.

A thalamocortical substrate for integrated information via critical synchronous bursting. Munn, B. R., Müller, E. J., Aru, J., Whyte, C. J., Gidon, A., Larkum, M. E., & Shine, J. M. (2023). Proceedings of the National Academy of Sciences, 120(46), e2308670120.

Change detection in the primate auditory cortex through feedback of prediction error signals. Obara, K., Ebina, T., Terada, S.-I., Uka, T., Komatsu, M., Takaji, M., … Matsuzaki, M. (2023). Nature Communications, 14, 6981.

Immune activation state modulates infant engram expression across development. Power, S. D., Stewart, E., Zielke, L. G., Byrne, E. P., Douglas, A., Ortega-de San Luis, C., … Ryan, T. J. (2023). Science Advances, 9(45).

Dopaminergic error signals retune to social feedback during courtship. Roeser, A., Gadagkar, V., Das, A., Puzerey, P. A., Kardon, B., & Goldberg, J. H. (2023). Nature, 623(7986), 375–380.

Hierarchical temporal prediction captures motion processing along the visual pathway. Singer, Y., Taylor, L., Willmore, B. D., King, A. J., & Harper, N. S. (2023). eLife, 12, e52599.

Neuronal implementation of the temporal difference learning algorithm in the midbrain dopaminergic system. Stetsenko, A., & Koos, T. (2023). Proceedings of the National Academy of Sciences, 120(45), e2309015120.

Forgotten memory storage and retrieval in Drosophila. Wang, C.-M., Wu, C.-Y., Lin, C.-E., Hsu, M.-C., Lin, J.-C., Huang, C.-C., … Chiang, H.-C. (2023). Nature Communications, 14, 7153.

Striatum-projecting prefrontal cortex neurons support working memory maintenance. Wilhelm, M., Sych, Y., Fomins, A., Alatorre Warren, J. L., Lewis, C., Serratosa Capdevila, L., … Helmchen, F. (2023). Nature Communications, 14, 7016.

Vestibular contribution to spatial encoding. Zanchi, S., Cuturi, L. F., Sandini, G., Gori, M., & Ferrè, E. R. (2023). European Journal of Neuroscience, 58(9), 4034–4042.

Sampling-based Bayesian inference in recurrent circuits of stochastic spiking neurons. Zhang, W.-H., Wu, S., Josić, K., & Doiron, B. (2023). Nature Communications, 14, 7074.

[collectivecartomancy]

Dandelion & Diabetes

Hey Everybody! Here’s my final for Rootwork Herbals People’s Medicine School.

Once it’s accepted, I’ll be a real, live community herbalist and I’m so excited! 🥹 🥹 🥹

Please feel free to put any questions or concerns in the comments, or email me directly at cyreejarelle@collectivecartomancy.com.

Thanks for bearing witness to this wonderful experience :)

As ever, wishing you well,

Cyree Jarelle

Dandelion/Taraxacum officinale: Overview

Dandelion is a perennial flowering herb that grows from a long taproot.

Its name has been associated with the Persian tark hashgun, which means wild endive.

Rodale's Illustrated Encyclopedia of Herbs, suggests an origin in the Greek taraxos is more likely. Taraxos is a Greek word for "disorder" and as Rodale's writes, akos means remedy.

This is the relationship that humans have kept with Dandelion. It's abundant, nigh unkillable, and easy to identify. The designation officinale refers to Dandelion's inclusion in early apothecaries. Its earliest written virtues are in the Tang Bencao, written during the Tang dynasty.

Dandelion has a history in Europe and the United States, where it's used to treat diseases of the liver and GI tract.

Dandelion is a bitter stimulant with diuretic and laxative properties.

Unlike other diuretics, dandelion does its work without depleting potassium in the body. This is due to the potassium richness of dandelion itself.

Type 2 Diabetes & Dandelion

Diabetes is an endocrine disorder. It primarily affects the pancreas, an organ in the digestive system found in the upper abdomen. The pancreas produces the hormones to control blood sugar, including insulin, glucagon, peptides, and somatostatin. It also makes enzymes essential to the digestion of food.

Diabetes has many risk factors and symptoms, but all types of diabetes involve insulin.

Type 2 Diabetes is characterized by the pancreas no longer making enough insulin to process sugar in one's diet. This can cause disruptions throughout the body, with notable impacts on the heart, liver, and eyes.

Wirngo et. al published "The Physiological Effects of Dandelion (Taraxacum Officinale) in Type 2 Diabetes" in 2016. There they attribute Dandelion's anti-diabetic properties to its "bioactive chemical components." These include "chicoric acid, taraxasterol (TS), chlorogenic acid, and sesquiterpene lactones," they write.

Wirngo et. al. assert that herbal medicine and other traditional medicines have "demonstrated potential to alleviate diabetic symptoms, enable recovery, and improve health." Dandelion does this by fighting inflammation, which can harm tissues throughout the body.

Dandelion's bitter taste is due to "sesquiterpene lactones." These include "taraxacolide, dihydro-lactucin, ixerin D, taraxinic acids, phenyl propanoids, and ainslioside." These constituents have have anti-inflammatory properties. Dandelion's foundational action as a bitter facilitates proper digestion.

Dandelion is so rich with CGA that it is a viable alternative to proprietary antioxidants. CGA itself is anti-diabetic, and it's best in it's natural form according to Wirngo. It also contains high levels of CRA, which combined with other inulin rich herbs such as Burdock Root and Chicory, helps people metabolize fats better.

When we metabolize fats better, it can decrease our cholesterol. CRA can also make us produce more bile, which breaks down fat and helps flush waste from our livers. CRA is also a strong anti-diabetic.

Bile breaks fat down into fatty acids. Fatty acids provide our bodies with a source of energy. Their presence also impacts the body's response to hormones, including insulin.

In fact, the way our bodies work with fatty acids can be very important for individuals with diabetes. This is because many people with type 2 diabetes have insulin resistance. Their bodies may not be able to store fatty acid as easily.

As a result, these fatty acids may deposit in the liver. This can cause Non-Alcoholic Fatty Liver disease, which allopathic doctors cannot treat well. They generally just tell patients to lose weight and lower their cholesterol. (Ask me how I know lol.)

According to Sears and Perry, "90 % of obese type-2 diabetic patients have NAFLD." Even people without diabetes are likely to have NAFLD though, due to poor nutritional options in the United States. They go on to note that researchers expect 50% of Americans to have NAFLD by 2030.

Dandelion is a beautiful medicine for people in this position because it supports the liver and helps lower cholesterol. It does this while also stimulating the metabolism, and aiding digestion. It's highly anti-oxidant and anti-carcinogenic. Dandelion root is also among the vegetables highest in beta-carotene. Beta-carotene becomes Vitamin A in the body.

Vitamin A improves eye function, helps the immune system and keeps our skin healthy. This is essential for people with diabetes, because they are prone to complications with all three, many of them serious.

Dandelion has the potential to ease symptoms of diabetes at low cost.

Specifically, it can lower the cholesterol, which is a major risk factor for the heart and liver complications of type 2 diabetes. This is essential because 80% of people with diabetes live in countries without high incomes.

As Chen et. al report in their article "Income-related inequalities in diagnosed diabetes prevalence among US adults, 2001−2018" the " burden of diabetes falls disproportionately on low-income populations."

In the United States, the people experiencing the strongest correlation between poverty and diabetes are Black and Latina women between the ages of 45-65.

These are the people who have the most to gain from dandelion medicine. It's free in most cases, can be cultivated even in small spaces, and it's cheap. It's identifiable even by children, and abundant nearly everywhere.

Dandelion reduces blood sugar through its caffeic, chicoric, and chlorogenic acid components. It also "effects glucose uptake directly and indirectly" through its "alkaloids, glycosides, amino acids, terpenoids, inorganic ions, steroids, carbohydrates, and galactomannan gum" components.

Importantly, Dandelion has extremely low toxicity.

Dandelion Vinegar

Many diabetics avoid alcohol. If you're not into alcohol, try this vinegar!

Ingredients:

- Fresh dandelion tops

- Fresh dandelion leaves

- Dried dandelion roots

- Apple Cider Vinegar (with the mother, if you can get your hands on some)

Directions

1. Clean a glass jar of your choice

2. Sterilize the jar with boiling water.

3. Let the jar dry

4. Wash your fresh ingredients so that they are completely free of dirt and bugs.

5. Grind all ingredients down as fine as you can using a clean coffee grinder, clean blender, or a mortar and pestle.

6. Fill cleaned and sterilized jar up halfway with Dandelion parts.

7. Cover Dandelion parts with vinegar, then fill jar up to 1/2-3/4inch from the top with vinegar.

8. Stir and release any air bubbles

9. Top with a plastic cap. If you have no plastic caps, use parchment paper between the metal of the jar top and the rim of the glass jar.

Works Cited

The Role and Anatomy of the Pancreas. Animated Pancreas Patient. Youtube. September 6, 2013. Accessed January 26, 2024. 

Article Source: Income-related inequalities in diagnosed diabetes prevalence among US adults, 2001−2018

Chen Y, Zhou X, Bullard KM, Zhang P, Imperatore G, et al. (2023) Income-related inequalities in diagnosed diabetes prevalence among US adults, 2001−2018. PLOS ONE 18(4): e0283450. https://doi.org/10.1371/journal.pone.0283450

Choi UK, Lee OH, Yim JH, Cho CW, Rhee YK, Lim SI, Kim YC. Hypolipidemic and antioxidant effects of dandelion (Taraxacum officinale) root and leaf on cholesterol-fed rabbits. Int J Mol Sci. 2010 Jan 6;11(1):67-78. doi: 10.3390/ijms11010067. PMID: 20162002; PMCID: PMC2820990.

Fan M, Zhang X, Song H, Zhang Y. Dandelion (Taraxacum Genus): A Review of Chemical Constituents and Pharmacological Effects. Molecules. 2023 Jun 27;28(13):5022. doi: 10.3390/molecules28135022. PMID: 37446683; PMCID: PMC10343869.

Gamboa-Gómez CI, Rocha-Guzmán NE, Gallegos-Infante JA, Moreno-Jiménez MR, Vázquez-Cabral BD, González-Laredo RF. Plants with potential use on obesity and its complications. EXCLI J. 2015 Jul 9;14:809-31. doi: 10.17179/excli2015-186. PMID: 26869866; PMCID: PMC4746997.

Kania-Dobrowolska M, Baraniak J. Dandelion (Taraxacum officinale L.) as a Source of Biologically Active Compounds Supporting the Therapy of Co-Existing Diseases in Metabolic Syndrome. Foods. 2022 Sep 15;11(18):2858. doi: 10.3390/foods11182858. PMID: 36140985; PMCID: PMC9498421.

Li J, Luo J, Chai Y, Guo Y, Tianzhi Y, Bao Y. Hypoglycemic effect of Taraxacum officinale root extract and its synergism with Radix Astragali extract. Food Sci Nutr. 2021 Feb 26;9(4):2075-2085. doi: 10.1002/fsn3.2176. PMID: 33841825; PMCID: PMC8020951.

Li Y, Chen Y, Sun-Waterhouse D. The potential of dandelion in the fight against gastrointestinal diseases: A review. J Ethnopharmacol. 2022 Jul 15;293:115272. doi: 10.1016/j.jep.2022.115272. Epub 2022 Apr 8. PMID: 35405251.

Pfingstgraf IO, Taulescu M, Pop RM, Orăsan R, Vlase L, Uifalean A, Todea D, Alexescu T, Toma C, Pârvu AE. Protective Effects of Taraxacum officinale L. (Dandelion) Root Extract in Experimental Acute on Chronic Liver Failure. Antioxidants (Basel). 2021 Mar 24;10(4):504. doi: 10.3390/antiox10040504. PMID: 33804908; PMCID: PMC8063808.

Sears B, Perry M. The role of fatty acids in insulin resistance. Lipids Health Dis. 2015 Sep 29;14:121. doi: 10.1186/s12944-015-0123-1. PMID: 26415887; PMCID: PMC4587882.

Seo SW, Koo HN, An HJ, Kwon KB, Lim BC, Seo EA, Ryu DG, Moon G, Kim HY, Kim HM, Hong SH. Taraxacum officinale protects against cholecystokinin-induced acute pancreatitis in rats. World J Gastroenterol. 2005 Jan 28;11(4):597-9. doi: 10.3748/wjg.v11.i4.597. PMID: 15641154; PMCID: PMC4250819.

Suo C, Polanski K, Dann E, Lindeboom RGH, Vilarrasa-Blasi R, Vento-Tormo R, Haniffa M, Meyer KB, Dratva LM, Tuong ZK, Clatworthy MR, Teichmann SA. Dandelion uses the single-cell adaptive immune receptor repertoire to explore lymphocyte developmental origins. Nat Biotechnol. 2024 Jan;42(1):40-51. doi: 10.1038/s41587-023-01734-7. Epub 2023 Apr 13. PMID: 37055623; PMCID: PMC10791579.

Wirngo FE, Lambert MN, Jeppesen PB. The Physiological Effects of Dandelion (Taraxacum Officinale) in Type 2 Diabetes. Rev Diabet Stud. 2016 Summer-Fall;13(2-3):113-131. doi: 10.1900/RDS.2016.13.113. Epub 2016 Aug 10. PMID: 28012278; PMCID: PMC5553762.

[hypeptide]

Peptides – unique medicines

In contrast to proteins and small molecules, peptides represent a unique class of pharmaceutical compounds that are biochemically and therapeutically distinct from both. As intrinsic signaling molecules for many physiological functions, peptides offer an opportunity for therapeutic intervention that closely mimics natural pathways. In recent years, peptides have received increasing attention as a therapeutic approach.

The origin and development of in vitro peptide drugs

Polypeptides are amino acid derivative compounds containing at least one amide (peptide) bond. From a structural point of view, polypeptides include various types of peptides, such as linear peptides, cyclic peptides, delipidated peptides, etc. According to function, they can also be divided into antibacterial peptides and hormones. Regulatory peptides, neuroactive peptides, etc. [1].

In the early 20th century, research on peptides focused primarily on the effects of human signaling hormones. Insulin is a classic example of endogenous hormone therapy. It was the first peptide drug to be used clinically and is by far the most commercially successful [2] because it revolutionized the treatment of type I diabetes.

Advantages, disadvantages and new attempts of peptide drugs

The key factors for the success of peptide drugs are the effectiveness, specificity and safety of the mode of action of the peptide [3]. The rapid clearance of peptides from the body means that they do not accumulate in tissues and are relatively less toxic to the human body [4]. However, the limitations of peptide drugs are as obvious as their advantages. ​

Since peptide drugs are easily cleared from the serum, this also results in low bioavailability of peptide drugs. Furthermore, peptides generally have poor cell membrane permeability, which limits their use in targeting intracellular targets. Therefore, the development of peptide therapeutics has mainly focused on extracellular targets. Moreover, because they cannot penetrate the intestinal mucosa and need to be administered subcutaneously or intravenously, the convenience and compliance of peptide drugs in actual treatment are reduced [4].

Improving the bioavailability and efficacy of peptide drugs is also a popular research area. There have also been advances in universal and reproducible oral administration, as well as intracellular delivery of peptide drugs [4]. Cyclic peptides, a category of peptide drugs, are an emerging form of drugs designed to solve problems.

Cyclotides—a new form of peptide drugs

Cyclic peptides (including cyclodeposition peptides and bicyclic peptides) have many favorable properties as therapeutic agents and research tools. Compared with linear peptides, cyclic peptides have better proteolytic resistance and structural stability.

Currently, several cyclic peptides have become highly successful drugs, including vancomycin (antibacterial), daptomycin (antibacterial), cyclosporine A (transplantation immunosuppressant), and caspofenside (antifungal). Inspired by natural products, chemists have developed many methods to prepare cyclic peptides via N-to-C, side chain to side chain, or main chain to side chain cyclization. Some synthetic cyclic peptides, such as eptifibatide (used to treat heart disease), octreotide (a somatostatin mimetic used to treat acromegaly and diarrhea), cyclic RGD peptide, and linalotide Peptides have also been approved by the FDA for clinical or late-stage clinical trials [5].

Peptidomimetics – chemically synthesized peptide drugs

In terms of new drug strategies, in order to overcome the instability defects of peptides, in addition to modifying polypeptides to varying degrees like cyclic peptides, peptidomimetic compounds are also another reasonable means.

Peptidomimetic compounds are a class of compounds whose pharmacophore simulates natural peptides or proteins in three-dimensional space and retains the ability to interact with biological targets and produce the same biological effects [6]. The difference is that peptoids avoid the inherent defects of natural polypeptides and improve biological activity and stability.

Peptide drugs, whether isolated from the innate immunity of various species (including mammals, amphibians, fish, insects, plants and bacteria), or designed based on structure-activity relationship research, serve as a new structural drug , all have great potential [7]. Here we introduce a high-throughput method that can quickly identify and find suitable drugs – constructing a peptide library.

Currently, there are nearly a hundred peptide drugs on the global market, and research on new peptide therapeutic drugs continues at a steady pace, with more than 100 peptides in the clinical development stage and another 400-600 peptides in the preclinical research stage [2 ]. The utilization of peptides as therapeutics has evolved over time and continues to evolve as drug development and treatment paradigms change.

references

Luca Gentilucci. Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization. Curr Pharm Des. 2010;16(28):3185-203.

Markus Muttenthaler. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021 Apr;20(4):309-325.

Keld Fosgerau. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015 Jan;20(1):122-8.

Antoine Henninot. The Current State of Peptide Drug Discovery: Back to the Future?. J Med Chem. 2018 Feb 22;61(4):1382-1414.

Patrick G Dougherty. Understanding Cell Penetration of Cyclic Peptides. Chem Rev. 2019 Sep 11;119(17):10241-10287. Epub 2019 May 14.

Josef Vagner. Peptidomimetics, a synthetic tool of drug discovery. Curr Opin Chem Biol. 2008 Jun; 12(3): 292–296.

Sylvie E Blondelle. Optimization and high-throughput screening of antimicrobial peptides. Curr Pharm Des. 2010;16(28):3204-11.

B Guixer. Chemically synthesized peptide libraries as a new source of BBB shuttles. Use of mass spectrometry for peptide identification. J Pept Sci. 2016 Sep;22(9):577-91.

Website: https://www.ks-vpeptide.com

[charaunofficial]

razoolio b like "Do you have Ghost Pancreas and how does their emission of somatostatin interact with how you are incorporeal and unaging"

* I do not blame Razoolio for being curious.

[willyskristina]

Carcinoid Syndrome Diarrhoea Treatment Market

Carcinoid Syndrome Diarrhoea Treatment Market Size, Share, Trends: Novartis AG Leads

Growing adoption of targeted therapies for improved symptom management

Market Overview: 

The Carcinoid Syndrome Diarrhoea Treatment Market is expected to develop at a 6.8% CAGR from 2024 to 2031. The market value is predicted to rise from USD XX billion in 2024 to USD YY billion in 2031. North America now dominates the market, accounting for the vast majority of worldwide sales. Key metrics include the increased prevalence of carcinoid syndrome, rising healthcare costs, and expanding awareness of rare diseases.

The market is steadily expanding as treatment options improve and an ageing population becomes increasingly susceptible to neuroendocrine tumours. Increased research and development initiatives aimed at innovative medicines are projected to drive market growth in the coming years.

DOWNLOAD FREE SAMPLE

Market Trends: 

The carcinoid syndrome diarrhoea therapy industry is seeing a considerable transition towards targeted medicines. These novel medicines are intended to specifically address the underlying causes of carcinoid syndrome, resulting in more effective symptom management and fewer side effects. Somatostatin analogues, in particular, have gained popularity because of their potential to block hormone release by neuroendocrine tumours.

An increasing understanding of illness pathophysiology and patient demand for treatments that improve quality of life are driving this trend. As research reveals novel molecular targets, the pipeline for targeted medicines grows, suggesting more personalized and efficient therapy choices for patients suffering from carcinoid syndrome diarrhoea.

Market Segmentation: 

Somatostatin analogues have emerged as the primary treatment for carcinoid syndrome diarrhea, having the biggest market share in the drug class sector. These medicines, which include octreotide and lanreotide, efficiently suppress the release of hormones that cause the devastating symptoms of carcinoid disease. Their effectiveness in treating diarrhea, combined with their ability to limit tumor growth, has cemented their status as first-line therapy.

Recent clinical trials have shown that somatostatin analogues are effective in the long run at controlling carcinoid syndrome symptoms. Phase III research published in the New England Journal of Medicine found that long-acting octreotide significantly reduced diarrhea frequency in 65% of individuals with carcinoid syndrome, compared to 26% in the placebo group. This persuasive data has helped to boost the market position of somatostatin analogues.

Market Key Players:

Novartis AG

Ipsen Pharma

Pfizer Inc.

Lexicon Pharmaceuticals, Inc.

Teva Pharmaceutical Industries Ltd.

Mylan N.V.

Contact Us:

Name: Hari Krishna

Email us: hari.krishna@aurorawaveintellects.com

Website: https://aurorawaveintellects.com/

[nithishkumble]

Neuroendocrine Tumor Treatment Market

Neuroendocrine Tumour Treatment Market Size, Share, Trends: Novartis AG Leads

Personalised medicine approaches gain traction in NET treatment strategies

Market Overview: 

The neuroendocrine tumour treatment market is expected to develop at a 10.2% CAGR from 2024 to 2031. The market is predicted to grow to XX USD by 2024 and YY USD by 2031. North America dominates the market, with significant indicators like rising incidence rates and advances in targeted therapy. The market is expanding rapidly due to increased awareness, improved diagnostic procedures, and the development of new treatment options.

DOWNLOAD FREE SAMPLE

Market Trends: 

The therapy landscape for neuroendocrine tumours (NETs) is shifting dramatically towards personalised medicine. This method customises therapy for individual patients based on their genetic profiles, tumour features, and biomarkers. Molecular profiling approaches are increasingly being utilised to detect specific genetic changes in NETs, enabling more targeted and effective treatments. For example, the discovery of somatostatin receptor expression in NETs prompted the creation of peptide receptor radionuclide therapy (PRRT), which has demonstrated encouraging outcomes in clinical trials. Furthermore, circulating tumour DNA (ctDNA) analysis is emerging as a non-invasive technique of monitoring therapy response and disease progression, allowing for real-time modifications to treatment programs. This shift towards personalised medicine is expected to spur innovation in NET treatments, improve patient outcomes, and potentially lower healthcare expenditures associated with unsuccessful therapy.

Market Segmentation: 

Targeted therapy dominates the treatment type segment, driven by its efficacy and reduced side effects compared to traditional chemotherapy. Targeted therapy has emerged as the dominant sector in the neuroendocrine tumour treatment industry, accounting for around YY% of the market in 2024. This dominance is due to the great specificity and efficacy of targeted medicines in treating NETs, which leads to better patient outcomes and fewer adverse effects than traditional chemotherapy. The clinical success of targeted treatments such as everolimus and sunitinib has resulted in their widespread use in NET therapy protocols.

Recent advances in targeted therapy for NETs have strengthened its market position. For example, in 2021, the United States Food and Drug Administration (FDA) approved surufatinib for the treatment of pancreatic and extra-pancreatic NETs, expanding patients' access to targeted medicines. This approval was based on two Phase III clinical trials that found significant increases in progression-free survival over placebo.

Market Key Players:

Novartis AG

Ipsen S.A.

Pfizer Inc.

Advanced Accelerator Applications (a Novartis company)

Hutchison China MediTech Limited

Tarveda Therapeutics

Contact Us:

Name: Hari Krishna

Email us: hari.krishna@aurorawaveintellects.com

Website: https://aurorawaveintellects.com/

[sifatipmerkezi]

Pankreas Nedir? Pankreas Nerede ve Ne İşe Yarar?

Pankreas, sindirim sistemi ve hormon üretimiyle ilgili önemli bir organ olup, karın boşluğunda mide ile ince bağırsak arasında yer alır. Hem endokrin hem de ekzokrin işlevlere sahip olan pankreas, sindirim enzimlerini ve hormonları üretir. Pankreasın ana görevlerinden biri, vücuttaki glukoz dengesini sağlamak için insülin ve glukagon gibi hormonları üretmektir. Ayrıca, sindirim sürecini destekleyen enzimler üreterek, yiyeceklerin parçalanmasını ve besin maddelerinin vücuda emilmesini sağlar.

Pankreas Nerede?

Karın bölgesinde, mide ve ince bağırsak arasında, omurganın önünde ve karaciğerin hemen altında yer alır. Yerdeki konumu, midenin arkasında, sol üst karnın biraz solunda yer alır. Pankreasın baş kısmı, duodenum adı verilen ince bağırsağın başlangıcına yakın bir bölgede bulunur, vücuda doğru uzanarak kuyruk kısmı dalağa yakın bir bölgeye kadar ilerler.

Pankreas Ne İşe Yarar?

İki ana işlevi vardır: sindirim ve hormon üretimi.

Sindirim: Pankreas, sindirim sisteminin düzgün çalışabilmesi için gerekli olan enzimleri üretir. Bu enzimler, yemeklerin mideye girdikten sonra ince bağırsakta aktif hale gelir ve proteinleri, yağları ve karbonhidratları parçalayarak sindirime yardımcı olur. Bu enzimler, amilaz (karbonhidratları), lipaz (yağları) ve proteaz (proteinleri) gibi maddelerdir.

Hormon Üretimi: Pankreas, kan şekeri seviyelerini düzenlemeye yardımcı olan insülin ve glukagon gibi hormonları üretir. İnsülin, kan şekerini düşürmeye yardımcı olurken, glukagon kan şekerini yükseltir. Bu hormonlar, vücudun enerji ihtiyacını karşılamak için önemli bir dengeyi sağlar. Ayrıca pankreas, somatostatin adı verilen başka bir hormon üretir, bu hormon vücutta diğer hormonların üretimini düzenler.

Pankreas Nerede Ağrı Yapar?

Pankreas ağrısı genellikle sol üst karın bölgesinde, özellikle mide bölgesinin hemen altında hissedilir. Bu ağrı, pankreasın iltihaplanması, enfeksiyonu veya diğer sağlık sorunları nedeniyle meydana gelebilir. Pankreas ağrısı bazen bel bölgesine veya sırtın üst kısmına da yayılabilir. Ayrıca, pankreas ağrısı yemeklerden sonra, özellikle yağlı yiyeceklerin tüketilmesinin ardından daha şiddetli olabilir. Pankreasın iltihaplanması durumunda (pankreatit), ağrı oldukça keskin olabilir ve hastalar genellikle mide bulantısı, kusma ve halsizlik gibi ek semptomlarla birlikte şiddetli karın ağrısı yaşarlar.

Pankreas Hastalıkları Nelerdir?

Pankreasın sağlığını etkileyen birçok hastalık vardır. Bunlar arasında en yaygın olanlar şunlardır:

Pankreatit: Pankreatit, pankreasın iltihaplanmasıdır. Genellikle aşırı alkol tüketimi, safra taşları veya bazı ilaçlar nedeniyle gelişir. Akut pankreatit, ani bir şekilde başlar ve şiddetli karın ağrısına yol açar. Kronik pankreatit ise daha uzun süreli bir hastalıktır ve pankreasın fonksiyonlarını kalıcı olarak etkileyebilir.

Pankreas Kanseri: Pankreas kanseri, pankreasın hücrelerinin anormal şekilde büyüyüp çoğalması sonucu oluşur. Genellikle geç teşhis edilir, çünkü erken dönemde belirgin semptomlar göstermez. Kanserin ileri evrelerinde, karın ağrısı, kilo kaybı, sarılık gibi belirtiler ortaya çıkabilir.

Diabetes Mellitus (Şeker Hastalığı): Pankreasın insülin üretimini etkileyen bir hastalık olan diabetes mellitus, pankreasın yetersiz insülin üretmesi nedeniyle vücutta yüksek kan şekeri seviyelerine yol açar. Bu durum, vücutta birçok komplikasyona neden olabilir.

Pankreas Kistleri: Pankreas içinde sıvı dolu kesecikler oluşabilir ve bu kistler bazen enfekte olabilir veya pankreasın fonksiyonlarını engelleyebilir. Kistler genellikle belirti vermez, ancak büyük ve ağrıya neden olabilecek kadar büyüyebilirler.

Pankreas Dışa Salınım Yetmezliği: Pankreasın sindirim enzimleri üretme kapasitesinin azalması, besinlerin yeterince sindirilememesine ve beslenme eksikliklerine yol açabilir.

Özel Pendik Şifa Tıp Merkezi’nin Hizmetleri

Pendik Şifa Tıp Merkezi, pankreas hastalıklarının teşhis ve tedavisinde uzmanlaşmış bir sağlık kurumudur. Pankreatit, pankreas kanseri, diyabet ve pankreas kistleri gibi durumların yönetimi konusunda deneyimli hekimlerle hizmet vermektedir. Pendik Şifa Tıp Merkezi, modern teşhis yöntemleri, ultrasonografi, bilgisayarlı tomografi (BT) ve manyetik rezonans görüntüleme (MRG) gibi ileri teknolojilerle pankreas hastalıklarını hızlı ve doğru bir şekilde teşhis eder.

Ayrıca, Pendik Şifa Tıp Merkezi'nde, pankreas hastalıklarının tedavisinde cerrahi müdahaleler, endoskopik işlemler ve medikal tedavilerle hastaların sağlığına kavuşmasına yardımcı olunmaktadır. Diyabet tedavisi için gerekli olan insülin tedavisi, ilaç yönetimi ve yaşam tarzı değişiklikleri konusunda da profesyonel destek verilmektedir. Pendik Şifa Tıp Merkezi, hasta odaklı yaklaşımıyla, pankreas hastalıklarının tedavisinde yüksek kaliteli hizmet sunmaktadır.

[jameswilliam4u]

Global Peptide Therapeutics Market Trends, Outlook, Growth, Share, Size & Forecast | 2024 - 2032

The global peptide therapeutics market is set to experience substantial growth in the coming years, driven by advancements in peptide synthesis technologies and the increasing application of peptides in various therapeutic fields, such as oncology, diabetes, and cardiovascular diseases. As of 2023, the peptide therapeutics market value stood at USD 36.1 billion, and it is anticipated to grow at a compound annual growth rate (CAGR) of 7.6% between 2024 and 2032. By the end of the forecast period, the market size is expected to reach approximately USD 69.9 billion.

Peptide therapeutics, often regarded as the future of medicine, offer advantages over traditional small molecule drugs, including higher specificity, fewer side effects, and the ability to target a broader range of diseases. With innovations in peptide synthesis technologies and an increasing pipeline of peptide-based drugs, the global market is witnessing rapid growth. This post delves into the segments, key players, market trends, growth drivers, and market outlook for peptide therapeutics, along with an analysis of the COVID-19 impact on the industry.

Get a Free Sample Report with Table of Contents: https://www.expertmarketresearch.com/reports/peptide-therapeutics-market/requestsample

Key Market Segments

The global peptide therapeutics market is highly segmented based on several factors, including product type, therapeutic application, route of administration, and region. Below is a breakdown of these segments:

1. By Product Type

Generic Peptides: These are often bioequivalent to branded peptide drugs and account for a significant share of the market due to their affordability and availability in large volumes.

Innovative Peptides: These are newly developed peptide-based drugs that offer higher specificity and efficacy in treating various diseases. With increasing R&D activities, the demand for innovative peptide therapeutics is expected to rise.

2. By Therapeutic Application

Peptide therapeutics are widely used in the treatment of various diseases. Some of the prominent therapeutic applications include:

Cancer: Peptides like somatostatin analogs and monoclonal antibody-based peptides have shown promise in targeting cancer cells.

Diabetes: Insulin peptides and glucagon-like peptides (GLP-1) are used for treating diabetes, a condition that is rising globally.

Cardiovascular Disorders: Peptide drugs for cardiovascular disease management, like B-type natriuretic peptide (BNP), are gaining traction.

Endocrine Disorders: Peptides for hormonal disorders, including pituitary-related diseases, are widely used.

Others: This includes areas such as central nervous system disorders, respiratory diseases, and inflammatory conditions.

3. By Route of Administration

Injectable: The injectable segment holds a dominant market share due to the established use of peptide therapeutics through subcutaneous injections and intravenous administration.

Oral: Oral peptide therapeutics are gaining traction due to patient preference for non-injectable forms. However, challenges remain regarding the stability of peptides in the gastrointestinal tract.

Nasal: Some peptides are administered nasally, especially for conditions affecting the central nervous system.

4. By Region

North America: The largest market share is held by North America, driven by advanced healthcare infrastructure, high healthcare spending, and the presence of leading pharmaceutical companies.

Europe: Europe is also a major player, especially with the growing adoption of peptide therapeutics for oncology and diabetes treatments.

Asia Pacific: The market in the Asia Pacific is growing rapidly, with countries like China, Japan, and India emerging as key hubs for peptide-based drug development.

Latin America & Middle East: Both these regions are witnessing steady growth due to improved healthcare access and awareness about peptide therapeutics.

Market Trends

Several key trends are shaping the global peptide therapeutics market:

1. Advancements in Peptide Synthesis Technologies

With continuous advancements in peptide synthesis technologies, such as solid-phase peptide synthesis (SPPS) and liquid-phase peptide synthesis (LPPS), the production of high-quality peptides at scale has become more efficient and cost-effective. This is accelerating the development and commercialization of new peptide drugs.

2. Increasing Investment in R&D

The growing number of clinical trials and the focus on developing novel peptide-based therapeutics for a wide range of diseases is a significant trend. Biopharmaceutical companies are investing heavily in R&D to bring innovative peptide therapeutics to market. Advances in peptide engineering, drug delivery systems, and peptide formulations are also driving market growth.

3. Emerging Applications of Peptides in Cancer Treatment

Peptides are showing promise as both targeted therapies and carriers for chemotherapeutic agents in cancer treatment. Peptide-based vaccines, immunotherapy, and targeted peptide-drug conjugates (PDCs) are making strides in oncology, offering hope for more effective and less toxic cancer therapies.

4. Personalized Medicine

Personalized or precision medicine is becoming a key driver for the growth of peptide therapeutics. Peptide biomarkers and tailored peptide therapies are expected to offer more specific treatments for individual patients based on genetic and molecular profiling.

5. Development of Oral Peptide Drugs

The oral administration of peptides is a game-changer, offering improved patient compliance compared to injectable therapies. Though peptide stability in the gastrointestinal tract remains a challenge, advancements in formulation technology are enabling the development of oral peptide drugs, making them more patient-friendly.

Growth Drivers

1. Rising Incidence of Chronic Diseases

The growing burden of chronic diseases, such as cancer, diabetes, cardiovascular diseases, and endocrine disorders, is driving the demand for peptide therapeutics. These diseases require long-term management, and peptides offer targeted and effective solutions.

2. Increasing Healthcare Expenditure

Rising healthcare expenditure in developed regions like North America and Europe is fostering the growth of the peptide therapeutics market. Governments and healthcare systems are increasingly investing in advanced treatments and therapies, including peptide-based drugs.

3. Aging Population

The global aging population is a critical driver for the peptide therapeutics market. Older adults are more susceptible to chronic diseases, and peptides offer an effective treatment for managing these conditions.

4. Regulatory Approvals and Market Expansion

The approval of new peptide-based therapeutics by regulatory agencies like the FDA and EMA is boosting market growth. As more peptides are approved for clinical use, their availability expands, and their adoption increases globally.

Key Players in the Peptide Therapeutics Market

Several major pharmaceutical and biotechnology companies dominate the peptide therapeutics market. These include:

Novo Nordisk: A leader in diabetes treatment, Novo Nordisk’s insulin peptides and GLP-1 receptor agonists like semaglutide are highly popular in the global market.

Ipsen: Ipsen is well-known for its peptide-based therapies in oncology, particularly for treating neuroendocrine tumours with somatostatin analogs.

Ferring Pharmaceuticals: Ferring is focused on peptide-based therapies for reproductive health and endocrinology.

Bachem AG: As a major player in the peptide synthesis and manufacturing sector, Bachem supplies the raw materials for peptide therapeutics and develops innovative peptide-based drugs.

Amgen: Amgen is developing several peptide-based therapies, particularly for cancer and metabolic diseases.

Sanofi: Sanofi is focusing on peptide-based treatments for diabetes and cardiovascular disorders, with liraglutide being a notable product in their portfolio.

Other prominent players in the peptide therapeutics space include Merck & Co., Inc., Teva Pharmaceuticals, AstraZeneca, and Novartis.

COVID-19 Impact on the Peptide Therapeutics Market

1. Disruptions in the Supply Chain

The COVID-19 pandemic caused significant disruptions in the global supply chain, including delays in the production and distribution of peptide-based therapeutics. However, as countries gradually recovered, the industry is now returning to pre-pandemic levels of production and distribution.

2. Increased Focus on Immunotherapies

The pandemic increased interest in peptide-based vaccines and immunotherapies to combat infectious diseases like COVID-19. The development of mRNA and peptide-based vaccines accelerated, potentially leading to a long-term increase in demand for peptide therapeutics.

3. Delayed Clinical Trials

Many clinical trials for peptide-based drugs were delayed during the pandemic due to restrictions on clinical visits and patient participation. However, as the world adapts to post-pandemic conditions, these trials are resuming, and the development of new peptide therapies is expected to progress.

Market Outlook and Future Trends

1. Continued Growth of the Market

The global peptide therapeutics market is expected to continue growing at a CAGR of 7.6% from 2024 to 2032. The development of new peptide drugs, especially in oncology and metabolic diseases, will contribute significantly to this growth.

2. Technological Advancements in Peptide Synthesis

As peptide synthesis technologies advance, the cost of production will decrease, making peptide therapeutics more accessible to a broader patient base. This will drive their adoption in emerging markets where healthcare access is improving.

3. Increasing Focus on Personalized Medicine

With the rise of genomic data, personalized medicine, and tailored peptide therapies will become a major growth avenue for the market. Peptides will be used to develop therapies that are specific to individual genetic profiles, leading to better patient outcomes.

FAQs

1. What are peptide therapeutics?

Peptide therapeutics are drugs made from short chains of amino acids (peptides) that are used to treat various diseases, including cancer, diabetes, and cardiovascular disorders.

2. What are the main therapeutic applications of peptides?

Peptides are widely used in oncology, diabetes, cardiovascular diseases, and endocrine disorders, among other therapeutic areas.

3. What are the growth drivers for the peptide therapeutics market?

Key drivers include the rising incidence of chronic diseases, advancements in peptide synthesis technologies, and increasing healthcare expenditure.

4. Who are the leading companies in the peptide therapeutics market?

Key players include Novo Nordisk, Ipsen, Ferring Pharmaceuticals, Bachem AG, Amgen, and Sanofi, among others.

5. How has COVID-19 impacted the peptide therapeutics market?

The pandemic disrupted supply chains and delayed clinical trials, but it also accelerated the development of peptide-based vaccines and therapies.

6. What is the future outlook for the peptide therapeutics market?

The market is expected to grow at a CAGR of 7.6% from 2024 to 2032, driven by advances in technology and increasing applications in various therapeutic areas.

Related Trending Related

https://www.expertmarketresearch.com/reports/silver-wound-dressing-markethttps://www.expertmarketresearch.com/reports/ischemic-heart-disease-drugs-markethttps://www.expertmarketresearch.com/clinical-trials/type-2-diabetes-drug-pipeline-analysis

[mitalipingale]

The Somatostatin Analogs Market in 2023 is US$ 7 billion, and is expected to reach US$ 13.17 billion by 2031 at a CAGR of 8.20%.

[jungian-julie]

SARMS during pregnancy

I'm taking MK-677 while pregnant.

MK-677 is better known as Ibutamoren and has become known for its properties to boost your muscle mass and lose fat quickly. It's a SARM and produces and releases growth hormone and reduces the inhibition of somatostatin. It also boosts ghrelin production, making you a lot more hungry.

It decreases the chance of miscarriage by 30% and if it are twins, it can help prevent growth restriction. It also has lots of benefits to skin, hair, nails and sleep quality.

In a couple weeks I'll have my first check up at the maternity clinic. Depending on the results from the blood test with regards to my liver values, glucose etc. and blood pressure measurements, I'll either continue or discontinue taking MK-677.

I'll stop anyway once I've been taking it for over 12 weeks. Then I'll have a break for a month before resuming, depending on what my health will be like.

I'm basically treating this pregnancy like the ultimate bulk. Since I'm also producing a natural form of Nandrolone (19-norandrosterone), which is an anabolic steroid. I'm not being as careful as I usually am with calories with a bulk, since I don't just need extra calories to gain muscle, but to also build a baby.

[exp-market-research111]

Carcinoid Tumor Drug Pipeline Analysis Report 2024

Carcinoid Tumor Market Outlook

Carcinoid tumors are uncommon, representing roughly 0.5% of all cancers. Typically diagnosed in individuals around their early 60s, these tumors mainly occur in the gastrointestinal system. In the United States, approximately 8,000 new cases of carcinoid tumors are reported annually. Treatment options include surgical intervention, chemotherapy, targeted therapies, and the development of new immunotherapies. These innovative treatments focus on slowing tumour growth and enhancing patient prognosis.

Carcinoid Tumor: Introduction

Carcinoid tumours are rare, slow-growing neuroendocrine tumours that typically develop in the gastrointestinal tract, lungs, or other endocrine organs. These tumours secrete hormones, such as serotonin, which can lead to a condition called carcinoid syndrome, characterised by symptoms like diarrhoea, flushing, and wheezing. Diagnosis often occurs late due to the insidious nature of symptoms, making treatment challenging. The development of new therapies focuses on controlling tumour growth, managing hormone secretion, and improving patient quality of life. Ongoing clinical trials and drug innovations are crucial to addressing the unmet needs in the treatment of these rare tumours.

Get a Free Sample Report with Table of Contents: https://www.expertmarketresearch.com/clinical-trials/carcinoid-tumor-drug-pipeline-analysis/requestsample

Carcinoid Tumor Treatment Overview

Carcinoid tumours are typically treated with surgical resection if possible, alongside therapies that control tumour growth and hormone secretion. The main treatment approaches include somatostatin analogues to reduce symptoms, chemotherapy for advanced disease, and targeted therapies. Early-stage disease may be managed with surgery alone, while more advanced stages require a combination of therapies, including systemic treatments and novel therapies under investigation.

Treatment options include somatostatin analogues such as octreotide and lanreotide to manage symptoms. Other approaches include chemotherapy, targeted therapies, and peptide receptor radionuclide therapy (PRRT). Targeted drugs, such as mTOR inhibitors and tyrosine kinase inhibitors, are emerging as promising options in advanced or resistant cases.

Drug Pipeline Therapeutic Assessment

Analysis by Route of Administration

Oral

Parenteral

Others

Analysis by Phase 

Preclinical Phase

Phase I

Phase II 

Phase III 

Phase IV 

Analysis by Drug Class

Monoclonal Antibody 

Peptides 

Polymer 

Small Molecule 

Gene Therapy

Carcinoid Tumor Drug Classes

Carcinoid tumor treatments utilise a range of drug classes, each designed to target specific pathways and mechanisms involved in cancer growth and survival. These diverse classes enhance the effectiveness of therapy and contribute to personalised treatment strategies. Understanding these drug classes is essential for optimising patient outcomes.

Monoclonal Antibody

Monoclonal antibodies are laboratory-engineered molecules designed to target specific antigens on the surface of tumour cells, which helps to block their growth and enhances the immune system's ability to destroy them. In carcinoid tumours, these antibodies may target receptors that drive hormone secretion or tumour proliferation, improving disease control. By blocking key growth signals or immune evasion mechanisms, monoclonal antibodies offer an effective and precise treatment strategy for managing advanced or metastatic carcinoid tumours.

Peptides

Peptide-based therapies consist of short chains of amino acids that can interfere with the processes responsible for tumour growth. In carcinoid tumours, somatostatin analogues are commonly used, which bind to specific receptors on the tumour cells, inhibiting the release of excess hormones such as serotonin. These therapies help to manage symptoms like flushing and diarrhoea associated with carcinoid syndrome, and stabilise tumour growth, offering symptom relief and improving patients’ quality of life.

Polymer

Polymers play an important role in cancer therapy by improving the delivery and stability of drugs. In carcinoid tumours, polymer-based drug delivery systems are used to target therapies more efficiently to the tumour site. This enhances the effectiveness of drugs by increasing their concentration at the tumor while reducing side effects on healthy tissues. Such advanced delivery mechanisms help to improve therapeutic outcomes, particularly for patients with advanced, resistant, or metastatic disease.

Small Molecule

Small molecules are drugs that are small enough to enter cells and interfere with cellular pathways responsible for tumour growth and survival. In carcinoid tumours, small molecules target specific signalling pathways involved in tumour proliferation and hormone production. By modulating these pathways, small molecules can help slow down tumour growth, manage symptoms, and provide an effective option for treating progressive or metastatic carcinoid tumours, where traditional therapies may be less effective.

Gene Therapy

Gene therapy aims to address the underlying genetic causes of cancer by modifying or replacing defective genes in tumour cells. For carcinoid tumours, gene therapy is being investigated to either restore normal cellular function or enhance the immune system’s ability to recognise and destroy tumour cells. This approach holds promise for offering long-term solutions in treating hard-to-treat, resistant cases of carcinoid tumours by targeting the molecular drivers of tumour growth.

Carcinoid Tumor- Pipeline Drug Profiles 

This section provides an overview of the various drugs used to treat carcinoid tumor. It covers their classifications, mechanisms of action, and methods of administration, offering essential insights for effective treatment strategies.

40 mg Paltusotine

Paltusotine is a selective somatostatin receptor type 2 agonist that is being investigated for its potential to control hormone secretion in patients with carcinoid syndrome. By reducing the serum levels of serotonin, it helps to manage the symptoms of diarrhoea, flushing, and wheezing associated with the syndrome. Clinical trials have shown promising results, especially for patients who have not responded to other standard therapies, making it a potential new option for long-term management.

Pasireotide (SOM230)

Pasireotide is a multireceptor-targeted somatostatin analogue used to manage the symptoms associated with neuroendocrine tumours, including carcinoid syndrome. It works by binding to somatostatin receptors and inhibiting the release of hormones like serotonin, which causes symptoms like diarrhoea and flushing. Pasireotide has shown efficacy in clinical trials, particularly in patients whose symptoms are not adequately controlled by first-line treatments. It offers an alternative therapeutic option for patients with advanced or resistant cases.

Quarfloxin

Quarfloxin is an investigational small molecule that targets the mitochondrial DNA replication machinery in cancer cells, causing tumour cell death. In carcinoid tumours, quarfloxin is being evaluated for its potential to inhibit tumour growth, particularly in patients with advanced or metastatic disease. Early clinical trials are assessing the drug’s safety and efficacy, and its combination with other therapies is being explored to improve overall treatment outcomes and manage resistant cases of carcinoid tumour.

Carcinoid Tumor: Competitor Landscape

The key features of the report include patent analysis, clinical trials, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 Novartis Pharmaceuticals

Headquartered in Basel, Switzerland, Novartis is a global leader in pharmaceutical innovation, with a strong presence in the oncology space. The company is known for its contributions to neuroendocrine tumour treatments, including the development of Pasireotide (SOM230) for managing carcinoid syndrome. Novartis continues to advance its research into targeted therapies and combination treatments, aiming to improve survival and quality of life for patients with rare, difficult-to-treat cancers such as carcinoid tumours.

CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, located in Rockville, Maryland, USA, is a biotechnology company focused on the development of novel therapies for rare and difficult-to-treat cancers, including carcinoid tumours. The company’s pipeline includes therapies designed to target tumour growth and hormone secretion in neuroendocrine cancers. By developing precision medicine approaches, CASI aims to provide more effective treatment options for patients with advanced or refractory cases of carcinoid tumours, addressing an unmet need in this area of oncology.

Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals, headquartered in San Diego, California, USA, is a leading biotechnology firm focused on the development of innovative treatments for endocrine diseases, including carcinoid tumours. The company is advancing several drug candidates that aim to modulate hormonal pathways and inhibit tumour growth. Crinetics’ approach to precision medicine aims to provide more personalised and effective treatments for patients with neuroendocrine cancers, and their research is expected to significantly improve treatment outcomes for carcinoid tumour patients.

Other key players in the landscape include Molecular Insight Pharmaceuticals, Inc., Neotropix, Ipsen, Cylene Pharmaceuticals, Lexicon Pharmaceuticals, TerSera Therapeutics LLC, Trio Medicines Ltd., and Endo Pharmaceuticals.

We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report..

[mukeshdalgavev123]

Carcinoid Syndrome Diarrhea Treatment Market Trends, Growth & Insights 2024

Carcinoid Syndrome Diarrhea Treatment Market Overview

The Global Carcinoid Syndrome Diarrhea Treatment Market has seen continuous development in the past couple of years and is anticipated to grow much further during the forecast period. The exploration introduces a total evaluation of the Carcinoid Syndrome Diarrhea Treatment Market and contains Future patterns, Current Growth Factors, mindful sentiments, certainties, chronicled information, and factually bolstered and industry-approved market information.

According to Straits Research, the global Carcinoid Syndrome Diarrhea Treatment market size was valued at USD XX Billion in 2023. It is projected to reach from USD XX Billion in 2024 to USD XX Billion by 2032, growing at a CAGR of 13.2% during the forecast period (2024–2032).

After identifying promising candidates, they undergo extensive testing and optimization to enhance their effectiveness, safety, and pharmacokinetic properties. This entire process of Carcinoid Syndrome Diarrhea Treatment Market may take several years and necessitates collaboration between scientists from diverse fields such as chemistry, biology, and pharmacology. Irrespective of the challenges encountered during Carcinoid Syndrome Diarrhea Treatment Market, it has the potential to revolutionize lives by providing new treatments for various diseases.

Request Sample Report of Global Carcinoid Syndrome Diarrhea Treatment Market @ https://straitsresearch.com/report/carcinoid-syndrome-diarrhea-treatment-market/request-sample

Competitive Analysis

The report contains an in-depth analysis of the vendor’s profile, including financial health, business units, key business priorities, SWOT, strategies, and views.

Lexicon Pharmaceuticals Inc.

Novartis International AG (Sandoz) (Switzerland)

Pharmascience Inc. (Canada)

Omega Laboratories Ltd. (Canada)

Teva Pharmaceutical Industries Ltd. (Israel)

Mylan N.V. (U.S.)

Ipsen Biopharmaceuticals Inc. (U.S.)

Sirtex Medical Limited (Australia)

BTG International Ltd. (U.K.)

Wockhardt Ltd.

The vendors have been identified based on the portfolio, geographical presence, marketing & distribution channels, revenue generation, and significant R&D investments.

Request Sample Report of Global Carcinoid Syndrome Diarrhea Treatment Market @ https://straitsresearch.com/report/carcinoid-syndrome-diarrhea-treatment-market/request-sample

Vendors across different verticals are planning for high investments in this market, and as a result, the market is expected to grow at an impressive rate in the upcoming years. The key players are adopting various organic and inorganic growth strategies such as mergers & acquisitions, collaboration & partnerships, joint ventures, and a few other strategies to be in a strong position in the global market.

Market Segmentation Analysis

The report provides a wide-ranging evaluation of the market, providing in-depth qualitative insights, historical data, and supportable projections along with the assumptions about the Carcinoid Syndrome Diarrhea Treatment Market size. The projections featured in the report have been derived using proven research methodologies and assumptions based on the vendor’s portfolio, blogs, white papers, and vendor presentations. Thus, the research report represents every side of the Carcinoid Syndrome Diarrhea Treatment Market and is segmented on the basis of regional markets, offerings, applications, and end-users.

By Treatment Type

Chemotherapy

Oral Therapy

Somatostatin Analog (SSA) Therapy

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By End User

Hospitals

Clinics

Cancer Research Institutes

Access Detailed Segmentation @ https://straitsresearch.com/report/carcinoid-syndrome-diarrhea-treatment-market/segmentation

Regional Analysis for Carcinoid Syndrome Diarrhea Treatment Market

The regional analysis offers a comprehensive view of the Carcinoid Syndrome Diarrhea Treatment Market sales and growth across global and country-level markets. It provides volume and market size data by region, with insights into growth trends in countries like the United States, Canada, Germany, France, China, Japan, and more. The analysis also covers major regions such as North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

Benefits

Carcinoid Syndrome Diarrhea Treatment Market Industry companies to ensure business continuity with powerful protection by constantly checking the report and representing attractive growth opportunities for the companies. Carcinoid Syndrome Diarrhea Treatment Market handles all the needs of the operators by allowing them to improve their services and concentrate on their core business. Carcinoid Syndrome Diarrhea Treatment Market Research aims to increase business agility and reduce operational and capital expenditure with improved technology rollouts and capacity planning. The report discusses service types and regions related to this Carcinoid Syndrome Diarrhea Treatment Market. Further, the report provides details about the major challenges affecting the market growth.

Buy Now: https://straitsresearch.com/buy-now/carcinoid-syndrome-diarrhea-treatment-market

Other Features of the Report:

Provides a thorough analysis of the key strategies with a focus on the corporate structure, R&D methods, localization strategies, production capabilities, sales, and performance in various companies.

Provides valuable insights into the product portfolio, including product planning, development, and positioning.

Thanks for reading this article; you can also get individual chapter-wise sections or region-wise report versions like North America, Europe, or Asia.

About Us:

StraitsResearch.com is a leading research and intelligence organization, specializing in research, analytics, and advisory services along with providing business insights & research reports.

Contact Us: Email: sales@straitsresearch.com Website: https://straitsresearch.com/